Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
TD Cowen Reiterates a Buy Rating on Boston Scientific Corporation (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the best strong buy healthcare stocks to buy now. On July 23, TD Cowen analyst Josh Jennings maintained a Buy rating on Boston Scientific Corporation ... Read More
Demystifying Boston Scientific: Insights From 9 Analyst Reviews
Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target; Steven Lichtman: Oppenheimer: Raises: Outperform: $125.00: $118.00: Danielle Antalffy: UBS: Raise ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus